DYNE-102

**DYNE-102** is an investigational Dyne Therapeutics oligonucleotide-conjugate program built on the company's FORCE platform for muscle-targeted delivery of nucleic acid therapeutics. Publicly available historical disclosures identify it as a preclinical candidate associated with **myotonic dystrophy type 1** and describe single-dose nonhuman primate proof-of-concept showing clinically relevant gene knockdown, but detailed public information on its exact payload sequence, final molecular composition, and current intended target transcript is limited. Based on Dyne's platform design and available descriptions, it appears to have been a **TfR1-targeted RNA-modulating oligonucleotide conjugate** intended to deliver a nucleic acid payload to muscle tissue; third-party pipeline sources indicate the program is **discontinued**. Because Dyne's later DM1 clinical asset is DYNE-101, DYNE-102 appears to be a distinct earlier code-named program rather than the currently advancing clinical candidate.

Other names

FORCE